We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1226
Praxis Precision Medicines
PRAX
$8.25B
$3K ﹤0.01%
+9
New +$2.64K
QSI icon
1227
Quantum-Si Incorporated
QSI
$166M
$3K ﹤0.01%
+343
New +$2.58K
QURE icon
1228
uniQure
QURE
$2.52B
$3K ﹤0.01%
158
– –
RPTX
1229
DELISTED
Repare Therapeutics
RPTX
$3K ﹤0.01%
127
– –
SRRK icon
1230
Scholar Rock
SRRK
$5.92B
$3K ﹤0.01%
118
– –
STOK icon
1231
Stoke Therapeutics
STOK
$1.83B
$3K ﹤0.01%
126
– –
VNDA icon
1232
Vanda Pharmaceuticals
VNDA
$310M
$3K ﹤0.01%
191
– –
KLRS
1233
Kalaris Therapeutics
KLRS
$79.5M
$3K ﹤0.01%
10
– –
ICVX
1234
DELISTED
Icosavax, Inc. Common Stock
ICVX
$3K ﹤0.01%
+114
New +$2.94K
RETA
1235
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3K ﹤0.01%
108
– –
RUBY
1236
DELISTED
Rubius Therapeutics, Inc
RUBY
$3K ﹤0.01%
307
– –
ENDP
1237
DELISTED
Endo International plc
ENDP
$3K ﹤0.01%
800
– –
ZGNX
1238
DELISTED
Zogenix, Inc.
ZGNX
$3K ﹤0.01%
191
– –
ABSI icon
1239
Absci
ABSI
$1.21B
$2K ﹤0.01%
+270
New +$3.07K
ABUS icon
1240
Arbutus Biopharma
ABUS
$871M
$2K ﹤0.01%
395
+235
+147% +$913
AFMD
1241
DELISTED
Affimed
AFMD
$2K ﹤0.01%
41
– –
ALLK
1242
DELISTED
Allakos
ALLK
$2K ﹤0.01%
158
-27
-15% -$2.21K
ANAB icon
1243
AnaptysBio
ANAB
$1.54B
$2K ﹤0.01%
60
– –
ANNX icon
1244
Annexon
ANNX
$814M
$2K ﹤0.01%
131
– –
AVIR icon
1245
Atea Pharmaceuticals
AVIR
$361M
$2K ﹤0.01%
+242
New +$3.77K
BCAB icon
1246
BioAtla
BCAB
$5.86M
$2K ﹤0.01%
+2
New +$2.56K
BLUE
1247
DELISTED
bluebird bio
BLUE
$2K ﹤0.01%
12
-6
-33% -$1.42K
CGEM icon
1248
Cullinan Oncology
CGEM
$1.07B
$2K ﹤0.01%
+127
New +$2.53K
DBC icon
1249
Invesco DB Commodity Index Tracking Fund
DBC
$1.65B
$2K ﹤0.01%
100
– –
DTIL icon
1250
Precision BioSciences
DTIL
$185M
$2K ﹤0.01%
7
– –
48 49
50
51 52

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.